Harvard Bioscience (HBIO) filed a registration statement Friday with the US Securities and Exchange Commission for the potential sale of up to $100 million of its securities via one or more offerings.
The registration covers common stock, preferred stock, warrants, and units, according to the filing.
The company said that the terms of each offering, including prices and conditions, will be disclosed in accompanying prospectus supplements.
The net proceeds from securities sales will be used for general corporate purposes, including working capital, research, manufacturing, and potential acquisitions, Harvard Bioscience said. Funds may also be invested in short-term instruments, the company added.
Shares of the company were down 1.4% in recent Friday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.